SCHEMBL22601587

SCHEMBL22601587

CC(C)(C)c1cc(N2CCCC2)ccn1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 7/20 0.51
CHKA P35790 1/20 0.47
HSD17B10 Q99714 2/20 0.43
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TERT O14746 3/20 0.41
ELOVL1 Q9BW60 1/20 0.40
LNPEP Q9UIQ6 1/20 0.39
PIK3CD O00329 1/20 0.38
PIK3CA P42336 1/20 0.38
PIK3CB P42338 1/20 0.38
PIK3CG P48736 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
ALOX15 P16050 1/20 0.38
KMT2A Q03164 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
IP6K1 Q92551 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22601451 0.98 HRH4 (0.54) HRH4CHKAHSD17B10LMNASMN1; SMN2
SCHEMBL20224121 0.86 HRH4 (0.56) HRH4HSD17B10LMNASMN1; SMN2MEN1
SCHEMBL20224125 0.85 LMNA (0.45) HSD17B10LMNASMN1; SMN2PIK3CDPIK3CA
SCHEMBL20224122 0.85 ADRB2 (0.51) HRH4ALDH1A1
SCHEMBL22601526 0.82 CHRNA7 (0.47) HRH4HSD17B10LMNASMN1; SMN2MEN1
SCHEMBL22601438 0.82 KDM4E (0.45) HRH4HSD17B10LMNASMN1; SMN2MEN1
SCHEMBL22601446 0.81 MEN1 (0.43) HRH4HSD17B10LMNASMN1; SMN2MEN1
SCHEMBL24008771 0.81 HRH4 (0.50) HRH4CHKAHSD17B10LMNASMN1; SMN2
SCHEMBL22601437 0.80 LMNA (0.49) HSD17B10LMNASMN1; SMN2MEN1MAPT
SCHEMBL22601449 0.80 HSD17B10 (0.55) HSD17B10LMNASMN1; SMN2MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200339530-A1 UREA DERIVATIVES AS INHIBITORS OF ASK1 HEPAGENE THERAPEUTICS, INC. (VG) 2020-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200339530-A1 UREA DERIVATIVES AS INHIBITORS OF ASK1 ATF1, ERN1, MAP3K1 HRH4 4032/4885CHKA 899/4885HSD17B10 2536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.